Appili Therapeutics Inc. APLI.TO
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 363.04% | -77.70% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 363.04% | -77.70% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 363.04% | -77.70% | |||
| SG&A Expenses | 2.43% | 293.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -41.10% | 255.81% | |||
| Operating Income | 44.63% | -309.29% | |||
| Income Before Tax | -66.36% | -9.04% | |||
| Income Tax Expenses | -82.61% | 327.14% | |||
| Earnings from Continuing Operations | -60.56% | -12.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -60.56% | -12.27% | |||
| EBIT | 44.63% | -309.29% | |||
| EBITDA | 44.65% | -310.39% | |||
| EPS Basic | -32.86% | -32.08% | |||
| Normalized Basic EPS | -38.10% | -27.27% | |||
| EPS Diluted | -32.86% | -32.08% | |||
| Normalized Diluted EPS | -38.10% | -27.27% | |||
| Average Basic Shares Outstanding | 20.58% | -14.48% | |||
| Average Diluted Shares Outstanding | 20.58% | -14.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||